logo
A Bold Mission to Hunt for Aliens on Venus Is Actually Happening

A Bold Mission to Hunt for Aliens on Venus Is Actually Happening

Gizmodo10-07-2025
A UK-based mission is aiming to settle, once and for all, whether life exists on Venus. The mission plans to send a probe to the planet in search of microbial life, not on the surface, of course, but in the Venusian clouds.
Over the past half-decade, scientists have detected the presence of phosphine and ammonia—two potential signs of biological activity—in Venus's clouds. On Earth, both gases are produced only by biological activity and industrial processes, and scientists are unsure of their origin on Venus.
Given the planet's thick, toxic atmosphere, scorching surface temperatures, and crushing surface pressure, a booming industrial economy seems unlikely. But microbes—which can thrive in Earth's hottest, most toxic environments—might be able to survive on Venus and produce these gases, researchers posit.
'Our latest data has found more evidence of ammonia on Venus, with the potential for it to exist in the habitable parts of the planet's clouds,' Jane Greaves, an astronomer at the University of Cardiff, said in a statement. 'There are no known chemical processes for the production of either ammonia or phosphine, so the only way to know for sure what is responsible for them is to go there.'
At this year's Royal Astronomical Society National Astronomy Meeting, researchers from the University of Cardiff presented their plan to search for and map phosphine, ammonia, and other hydrogen-rich gases that might indicate the presence of microbial life on Earth's twin.
The mission, called the Venus Explorer for Reduced Vapours in the Environment (VERVE), will send a CubeSat-sized probe aboard the European Space Agency's EnVision mission—a larger mission designed to probe Venus's surface and interior, scheduled for launch in 2031. VERVE will detach upon arrival and carry out an independent atmospheric survey.
Researchers first detected phosphine in Venus's clouds in 2020. The finding was controversial, however, as follow-up studies failed to replicate the results.
But a subsequent project, JCMT–Venus, designed to study the molecular composition of Venus's atmosphere using the James Clerk Maxwell Telescope in Hawaii, offered a possible explanation for these disparate findings. Researchers tracked the phosphine signature over time and found it could only be detected at night, as it was destroyed by sunlight. They also discovered that the amount of gas in Venus's atmosphere varied over time.
Last year, at the National Astronomy Meeting, researchers also reported the detection of ammonia in Venus's atmosphere.
Although surface temperatures on Venus reach around 450 degrees Celsius, conditions become much more reasonable about 31 miles (50 kilometers) above the surface, where temperatures range from 30 degrees Celsius to 70 degrees Celsius. Researchers believe it may be possible for extremophiles—like those found in Earth's hydrothermal vents and deep-sea trenches—to survive in these conditions.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EMA Committee Backs Tryngolza for Rare Lipid Disorder
EMA Committee Backs Tryngolza for Rare Lipid Disorder

Medscape

time18 minutes ago

  • Medscape

EMA Committee Backs Tryngolza for Rare Lipid Disorder

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization in the European Union to Tryngolza (olezarsen; Ionis Ireland Limited) for treating adults with familial chylomicronemia syndrome (FCS). The drug, to be available as an 80-mg solution for injection in prefilled pens, will be used as an adjunct to dietary modifications in adult patients with genetically confirmed FCS. FCS is a rare inherited disorder caused by loss-of-function variants in LPL or related genes, leading to absent or severely reduced lipoprotein lipase activity. This results in extreme hypertriglyceridemia (often > 880 mg/dL or 10 mmol/L) due to accumulation of chylomicrons and very low-density lipoprotein (VLDL). FCS affects about 13 people per million in Europe and causes recurrent acute pancreatitis (in about 85% of patients), severe abdominal pain, and chronic complications. Standard lipid-lowering therapies are typically ineffective, and strict fat-restricted diets are difficult to maintain, making disease management challenging. Tryngolza, a lipid-modifying agent, is an antisense oligonucleotide-GalNAc₃ carbohydrate ligand conjugate that targets apolipoprotein C-III (apoC-III) mRNA in hepatocytes. The GalNAc₃ moiety facilitates selective uptake by liver cells and, once internalized, the antisense oligonucleotide blocks apoC-III protein synthesis. This enhances lipolysis and hepatic clearance of triglyceride-rich lipoproteins, including VLDL and chylomicrons, ultimately lowering plasma triglyceride levels. Significant Benefits in Clinical Trials The CHMP decision relied on positive findings from the phase 3 Balance trial involving 66 patients with genetically confirmed FCS and severe hypertriglyceridemia, including 71% with a history of acute pancreatitis. Participants were randomly assigned to receive Tryngolza 80 mg, 50 mg, or placebo subcutaneous injections every 4 weeks for 49 weeks. Tryngolza 80 mg significantly reduced triglyceride levels by 43.5 percentage points at 6 months compared with placebo, while the 50-mg dose showed a nonsignificant reduction. Both doses markedly decreased apoC-III concentrations, with the 80-mg group achieving a 73.7-percentage point drop and the 50-mg group a 65.5-percentage point decline vs placebo. Acute pancreatitis events decreased significantly, with 11 episodes occurring among placebo recipients compared with just one in each Tryngolza group over 53 weeks, indicating an 88% risk reduction. The most common side effects of Tryngolza include injection-site erythema, headache, arthralgia, and vomiting.

Polymyalgia Rheumatica Not Linked to Increased Mortality
Polymyalgia Rheumatica Not Linked to Increased Mortality

Medscape

timean hour ago

  • Medscape

Polymyalgia Rheumatica Not Linked to Increased Mortality

TOPLINE: In a long-term follow-up study, patients with isolated polymyalgia rheumatica (PMR) and biopsy-confirmed giant cell arteritis (GCA) had no increased all-cause mortality compared with matched individuals; men with PMR showed lower mortality. METHODOLOGY: Researchers assessed long-term all-cause mortality in patients with PMR using data from a prospective, population-based inception cohort in Norway between 1987 and 1997 that was followed for 38 years. They included 274 patients with isolated PMR (mean age at diagnosis, 71.9 years; 66.1% women) and 63 patients with GCA (mean age at diagnosis, 71.6 years; 76.2% women), of whom 22 had coexisting PMR and GCA. PMR was defined with the fulfilment of criteria suggested by Bird and colleagues, and the diagnosis of GCA was confirmed with a positive temporal artery biopsy. Each case of PMR and GCA was matched with 15 individuals from the population registry on the basis of sex, age at inclusion, and residency, resulting in a total of 4110 and 945 individuals, respectively. Mortality and survival were assessed using the standard mortality ratio (SMR), with patients being followed up till death or until December 2024. TAKEAWAY: Among all patients with PMR, 96% had died by the end of the study, with a mean follow-up duration of 14 years and a maximum of 35.3 years. All-cause mortality in patients with PMR or GCA did not differ significantly from that in matched individuals. Men with PMR had significantly lower all-cause mortality (SMR, 0.77; 95% CI, 0.62-0.95); no significant sex-related differences were observed in patients with GCA. The overall cumulative survival in patients with PMR or GCA was not significantly different from that in the matched individuals. IN PRACTICE: "Our findings align with previous evidence reinforcing that isolated PMR does not sig­nificantly impact survival negatively, offering reassurance to both patients and clinicians regarding its long-term prognosis," the authors wrote. SOURCE: This study was led by Stig Tengesdal, Sørlandet Hospital, Kristiansand, Norway. It was published online on July 21, 2025, in Arthritis Research & Therapy. LIMITATIONS: The Bird's criteria may have relatively poor specificity for PMR. The prevalence of large vessel vasculitis may have been underestimated in the PMR cohort. Cases of malignancy could not be identified and excluded as data from medical charts were limited. DISCLOSURES: This study did not receive any specific funding. The authors declared having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Older Breast Cancer Patients Face Inconsistent Bone Care
Older Breast Cancer Patients Face Inconsistent Bone Care

Medscape

timean hour ago

  • Medscape

Older Breast Cancer Patients Face Inconsistent Bone Care

TOPLINE: Bone health management for older women with breast cancer receiving aromatase inhibitors (AIs) varied substantially across five UK hospitals. Despite the higher risk for fractures, women older than 80 years were less likely to receive DEXA scans or bisphosphonates, highlighting the urgent need for standardised bone monitoring and treatment in frail older patients. METHODOLOGY: This secondary analysis of the multicentre Age Gap study included 529 women (age, ≥ 70 years) with oestrogen receptor-positive early breast cancer who received AIs, either as primary or adjuvant treatment, at five hospitals in the UK. Researchers collected comprehensive data including the type of endocrine therapy, DEXA scan results, bisphosphonate usage, calcium and vitamin D supplementation, and the incidence of fractures during or after AI therapy. Frailty was assessed using a modified Rockwood Frailty Index, with scores being calculated across 75 variables to categorise patients as robust (< 0.08), prefrail (0.08-0.25), or frail (> 0.25). TAKEAWAY: Overall, 67% of patients had baseline DEXA scans. Of these, 42% were osteopenic and 18% osteoporotic. Scans were more common in 70- to 79-year-olds than in those aged 80 years or older and in women undergoing surgery than in those undergoing primary endocrine therapy, with marked variation across centres (P < .001 for all). Among patients receiving AI therapy, 43% were prescribed bisphosphonates, especially those who had surgery (hazard ratio [HR], 1.36; P = .04) and those aged 70-79 years (HR, 1.31; P = .02); 33% had vitamin D plus calcium along with bisphosphonates. During follow-up, 23% of patients had fractures, with significant variation across centres (P = .02), and 38% of these patients had received prior bisphosphonates. Although 94% of patients were frail or prefrail, frailty did not correlate with baseline hip (P = .10) or spine (P = .89) T scores. Bisphosphonates plus AIs were prescribed in 70% of non-frail participants vs 43% of prefrail and 47% of frail participants (P = .02). IN PRACTICE: "Patient's age and general health influence bone health decision making, with older and frailer patients often receiving non-standard care. Despite national and international recommendations, there is still wide variation in bone health management, highlighting the need for further education and standardised bone health care in older women with breast cancer," the authors wrote. SOURCE: This study was led by Elisavet Theodoulou, University of Sheffield, Sheffield, England. It was published online on July 18, 2025, in the Journal of Geriatric Oncology. LIMITATIONS: The study's inclusion of only five hospital sites limited the ability to draw broader conclusions about bone health management practices across a wider range of centres. Additionally, the interpretation of the results was complicated by the introduction of adjuvant bisphosphonates during the study period, making the cohort unstable in terms of bisphosphonate usage indications. DISCLOSURES: The Age Gap study was supported by the National Institute for Health and Care Research Programme Grants for Applied Research. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store